ClinicalTrials.gg
CompletedNCT00862420Updated Jul 17, 2012

Safety Evaluation of Clopidogrel Sulfate in Patients With Peripheral Arterial Disease

A Phase 3 interventional study of clopidogrel (SR25990) and ticlopidine in Peripheral Arterial Disease (PAD), sponsored by Sanofi. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2012-07-17.

Sponsored by Sanofi · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
431
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing clopidogrel in Peripheral Arterial Disease — 3 open to participants now, 4 under way, none of them phase 3. Clopidogrel · Peripheral Arterial Disease.

Enrollment
2nd of 10
431 · median 205
Started
2009
the only one that year
Phase 3
3 of 10
none open now
Registered
3rd of 10
by date
Lead sponsor
2 of 10
Sanofi

Among the 10 studies testing clopidogrel in Peripheral Arterial Disease, this one is the 2nd largest by enrollment, is the only one that started in 2009, is one of 3 in phase 3, and was the 3rd registered.

Peripheral Arterial Disease

1,377 studies on the registry are indexed under Peripheral Arterial Disease; 275 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

3 of the 10 studies testing clopidogrel in Peripheral Arterial Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About clopidogrel

Clopidogrel: first FDA approval 1997 (PLAVIX), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 192 Peripheral Arterial Disease studies recruiting now, 138 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing clopidogrel in Peripheral Arterial Disease, or all of them as a file.
02

Study summary

Primary objective:

  • To evaluate whether 12 weeks of clopidogrel is superior to ticlopidine in terms of lower risk of the safety events of interests in patients with peripheral arterial disease (PAD)

Secondary objectives:

  • To compare the risk of bleeding adverse events, serious adverse events and overall safety of clopidogrel with ticlopidine
  • To compare the risk of vascular events of clopidogrel with ticlopidine
  • To document the long-term safety of clopidogrel for a total of 52 weeks
  • To document the vascular events of clopidogrel for a total of 52 weeks
03

Conditions studied

  • Peripheral Arterial Disease (PAD)

Keywords

  • Platelet aggregation inhibitors
  • Peripheral arterial disease (PAD)
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Documented symptomatic peripheral arterial disease (one or both of the following two primary criteria must be satisfied):

  • Current intermittent claudication with Ankle Brachial Index (ABI) \< 0.90
  • A history of intermittent claudication together with previous related intervention in a leg

Exclusion criteria

Exclusion Criteria:

  • Patients who had acute atherothrombotic events or any invasive therapies within 30 days before the randomization, or patients who planned any invasive therapies within 12 weeks after the randomization
  • Bleeding diathesis, coagulopathy and present bleeding disease
  • Previous intracranial bleeding or hemorrhagic stroke
  • Uncontrolled hypertension

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
431 participants (actual)

Study arms

  • Experimental
    Clopidogrel

    75 mg clopidogrel once daily from Day 1 to Week 12

    Drug: clopidogrel (SR25990)

  • Active comparator
    Ticlopidine

    200 mg ticlopidine once daily from Day 1 to Week 12

    Drug: ticlopidine

Interventions

06

What researchers measure

Primary outcomes

  1. Safety events of interest including clinical significant bleeding, blood disorders, hepatic dysfunction and other serious adverse drug reactions (death, hospitalization...)

    Time frame: Week 12 (on treatment)

Secondary outcomes

  1. Bleeding adverse events, Serious adverse events, Overall safety

    Time frame: Week 12, 52 (on treatment)

  2. Vascular events

    Time frame: Week 12, 52 (on study)

  3. Safety events of interest (see above)

    Time frame: Week 52 (on treatment)

07

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Tokyo, Japan
08

References and documents

Publications

  • Shigematsu H, Komori K, Tanemoto K, Harada Y, Nakamura M. Clopidogrel for Atherothrombotic Event Management in Patients with Peripheral Arterial Disease (COOPER) Study: Safety and Efficacy of Clopidogrel versus Ticlopidine in Japanese Patients. Ann Vasc Dis. 2012;5(3):364-75. doi: 10.3400/avd.oa.12.00039. PubMed 23555538 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2009
First posted
Mar 16, 2009
Start
Feb 2009
Primary completionActual
May 2011
CompletionActual
May 2011
Last update
Jul 17, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00862420
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 16, 2009
Start date
Feb 2009
Primary completion
May 2011
Completion
May 2011
Last update
Jul 17, 2012

Study contacts

Hiroshi Shigematsu, Head Professor/MD/PhD
principal investigator · Second Department of Surgery (Vascular Surgery), Tokyo Medical University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clopidogrel

Start the discussion